CDCA5 and tumors

doi:10.3760/cma.j.cn371439-20200810-00007

Abstract

Abstract:

Cohesion between sister chromatids occurs during DNA replication, is regulated by cohesin, and depends on acetylation of cell division cycle associated 5 (CDCA5) and cohesin. WAPL can promote dissociation of cohesin from DNA, and CDCA5 can antagonize the effect of WAPL and stabilize sister chromatids cohesion by stabilizing the binding of cohesin to DNA. CDCA5 mRNA has a high transcription level in a variety of tumor cell lines, suggesting that CDCA5 may be related to the higher malignant proliferation activity of tumor cells, and has been confirmed in various tumors such as liver cancer and lung cancer, and CDCA5 may be a potential targeted molecule for the treatment of malignant tumors.

Key words: Neoplasms, Cell division cycle associated 5, Sororin, Cohesion

He Peidong, Li Zijian. CDCA5 and tumors[J]. Journal of International Oncology, 2021, 48(1): 41-44.

References 29

[1]	Chang IW, Lin VC, He HL, et al. CDCA5 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder[J]. Am J Transl Res, 2015,7(4):710-722. pmid: 26064439
[2]	Fu G, Xu Z, Chen X, et al. CDCA5 functions as a tumor promoter in bladder cancer by dysregulating mitochondria-mediated apoptosis, cell cycle regulation and PI3k/AKT/mTOR pathway activation[J]. J Cancer, 2020,11(9):2408-2420. DOI: 10.7150/jca.35372. pmid: 32201512
[3]	Cai C, Wang W, Tu Z. Aberrantly DNA methylated-differentially expressed genes and pathways in hepatocellular carcinoma[J]. J Cancer, 2019,10(2):355-366. DOI: 10.7150/jca.27832. pmid: 30719129
[4]	Wan Z, Zhang X, Luo Y, et al. Identification of hepatocellular carcinoma-related potential genes and pathways through bioinformatic-based analyses[J]. Genet Test Mol Biomarkers, 2019,23(11):766-777. DOI: 10.1089/gtmb.2019.0063. pmid: 31633428
[5]	Chen H, Chen J, Zhao L, et al. CDCA5, transcribed by E2F1, promotes oncogenesis by enhancing cell proliferation and inhibiting apoptosis via the AKT pathway in hepatocellular carcinoma[J]. J Cancer, 2019,10(8):1846-1854. DOI: 10.7150/jca.28809. doi: 10.7150/jca.28809 pmid: 31205541
[6]	Tian Y, Wu J, Chagas C, et al. CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC)[J]. BMC Cancer, 2018,18(1):1187. DOI: 10.1186/s12885-018-5072-4. doi: 10.1186/s12885-018-5072-4 pmid: 30497429
[7]	Wang J, Xia C, Pu M, et al. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma[J]. Oncol Rep, 2018,40(4):1875-1884. DOI: 10.3892/or.2018.6579. doi: 10.3892/or.2018.6579 pmid: 30015982
[8]	Shen Z, Yu X, Zheng Y, et al. CDCA5 regulates proliferation in hepatocellular carcinoma and has potential as a negative prognostic marker[J]. Onco Targets Ther, 2018,11:891-901. DOI: 10.2147/OTT.S154754. pmid: 29503564
[9]	Lin Y, Liang R, Ye J, et al. A twenty gene-based gene set variation score reflects the pathological progression from cirrhosis to hepatocellular carcinoma[J]. Aging (Albany NY), 2019,11(23):11157-11169. DOI: 10.18632/aging.102518.
[10]	Zhang Z, Shen M, Zhou G. Upregulation of CDCA5 promotes gastric cancer malignant progression via influencing cyclin E1[J]. Biochem Biophys Res Commun, 2018,496(2):482-489. DOI: 10.1016/j.bbrc.2018.01.046. pmid: 29326043
[11]	Chen T, Huang Z, Tian Y, et al. Role of triosephosphate isomerase and downstream functional genes on gastric cancer[J]. Oncol Rep, 2017,38(3):1822-1832. DOI: 10.3892/or.2017.5846. doi: 10.3892/or.2017.5846 pmid: 28737830
[12]	Nguyen MH, Koinuma J, Ueda K, et al. Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis[J]. Cancer Res, 2010,70(13):5337-5347. DOI: 10.1158/0008-5472.can-09-4372. pmid: 20551060
[13]	Wu Q, Zhang B, Sun Y, et al. Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis[J]. Onco Targets Ther, 2019,12:3545-3563. DOI: 10.2147/ott.s198621. doi: 10.2147/OTT.S198621 pmid: 31190860
[14]	Huang J, Li Y, Lu Z, et al. Analysis of functional hub genes identifies CDC45 as an oncogene in non-small cell lung cancer-a short report[J]. Cell Oncol (Dordr), 2019,42(4):571-578. DOI: 10.1007/s13402-019-00438-y.
[15]	Ladurner R, Kreidl E, Ivanov MP, et al. Sororin actively maintains sister chromatid cohesion[J]. EMBO J, 2016,35(6):635-653. DOI: 10.15252/embj.201592532. pmid: 26903600
[16]	Zhang N, Pati D. C-terminus of Sororin interacts with SA2 and regulates sister chromatid cohesion[J]. Cell Cycle, 2015,14(6):820-826. DOI: 10.1080/15384101.2014.1000206. pmid: 25608232
[17]	Nishiyama T, Ladurner R, Schmitz J, et al. Sororin mediates sister chromatid cohesion by antagonizing Wapl[J]. Cell, 2010,143(5):737-749. DOI: 10.1016/j.cell.2010.10.031. doi: 10.1016/j.cell.2010.10.031 pmid: 21111234
[18]	Nishiyama T, Sykora MM, Huis in't Veld PJ, et al. Aurora B and Cdk1 mediate Wapl activation and release of acetylated cohesin from chromosomes by phosphorylating Sororin[J]. Proc Natl Acad Sci U S A, 2013,110(33):13404-13409. DOI: 10.1073/pnas.1305020110. doi: 10.1073/pnas.1305020110 pmid: 23901111
[19]	Borton MT, Rashid MS, Dreier MR, et al. Multiple levels of regulation of sororin by Cdk1 and Aurora B[J]. J Cell Biochem, 2016,117(2):351-360. DOI: 10.1002/jcb.25277. doi: 10.1002/jcb.25277 pmid: 26177583
[20]	Zhang N, Pati D. Sororin is a master regulator of sister chromatid cohesion and separation[J]. Cell Cycle, 2012,11(11):2073-2083. DOI: 10.4161/cc.20241. doi: 10.4161/cc.20241 pmid: 22580470
[21]	Liu J, Meng H, Li S, et al. Identification of potential biomarkers in association with progression and prognosis in epithelial ovarian cancer by integrated bioinformatics analysis[J]. Front Genet, 2019,10:1031. DOI: 10.3389/fgene.2019.01031. pmid: 31708970
[22]	Shen A, Liu L, Chen H, et al. Cell division cycle associated 5 promotes colorectal cancer progression by activating the ERK signaling pathway[J]. Oncogenesis, 2019,8(3):19. DOI: 10.1038/s41389-019-0123-5. pmid: 30808873
[23]	Xu J, Zhu C, Yu Y, et al. Systematic cancer-testis gene expression analysis identified CDCA5 as a potential therapeutic target in esophageal squamous cell carcinoma[J]. EBioMedicine, 2019,46:54-65. DOI: 10.1016/j.ebiom.2019.07.030. doi: 10.1016/j.ebiom.2019.07.030 pmid: 31324603
[24]	Zhou Q, Ren J, Hou J, et al. Co-expression network analysis identified candidate biomarkers in association with progression and prognosis of breast cancer[J]. J Cancer Res Clin Oncol, 2019,145(9):2383-2396. DOI: 10.1007/s00432-019-02974-4. doi: 10.1007/s00432-019-02974-4 pmid: 31280346
[25]	Fu Y, Zhou QZ, Zhang XL, et al. Identification of hub genes using co-expression network analysis in breast cancer as a tool to predict different stages[J]. Med Sci Monit, 2019,25:8873-8890. DOI: 10.12659/msm.919046. doi: 10.12659/MSM.919046 pmid: 31758680
[26]	Phan NN, Wang CY, Li KL, et al. Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient[J]. Oncotarget, 2018,9(6):6977-6992. DOI: 10.18632/oncotarget.24059. pmid: 29467944
[27]	Kato T, Lee D, Wu L, et al. SORORIN and PLK1 as potential the-rapeutic targets in malignant pleural mesothelioma[J]. Int J Oncol, 2016,49(6):2411-2420. DOI: 10.3892/ijo.2016.3765. pmid: 27840913
[28]	Tokuzen N, Nakashiro K, Tanaka H, et al. Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma[J]. Oncotarget, 2016,7(3):2343-2353. DOI: 10.18632/oncotarget.6148. doi: 10.18632/oncotarget.6148 pmid: 26497678
[29]	Xu T, Ma M, Dai J, et al. Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma[J]. Hum Pathol, 2018,75:137-145. DOI: 10.1016/j.humpath.2018.02.009. pmid: 29452217

CDCA5 and tumors

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 29

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.